On January 21, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that it will host an event for institutional investors and analysts dedicated to its Antibody-Drug Conjugate (ADC) strategy, and particularly Nectin-4, the target of its lead antibody-drug candidate program, IPH4502 (Press release, Innate Pharma, JAN 21, 2025, View Source [SID1234649791]). The event will be held in New York in a hybrid format on Wednesday, February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT.
"As we just updated our strategy with a focus on our ANKET platform and ADC programs, this meeting will be an opportunity to share the latest scientific and clinical advancements related to Nectin-4 and its potential in cancer treatment," said Jonathan Dickinson, Chief Executive Officer of Innate Pharma
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Event details:
Date: February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT
Registration: If you would like to attend the event, please register at this link: View Source
For those who are unable to attend in person, a live webcast and replay will be on Innate Pharma’s website at: View Source
About IPH4502
IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, including urothelial carcinoma, where Nectin-4 expression is highest, breast cancer, non-small cell lung cancer and gastro-intestinal cancer.
In non-clinical models, IPH45 is well tolerated and shows anti-tumor activity in vitro and in vivo.
In September 2024, the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502.